{
    "id": 5199,
    "fullName": "FLT4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FLT4 (VEGFR3) over exp indicates an over expression of the Flt4 (Vegfr3) protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2324,
        "geneSymbol": "FLT4",
        "terms": [
            "FLT4",
            "CHTD7",
            "FLT-4",
            "FLT41",
            "LMPH1A",
            "LMPHM1",
            "PCL",
            "VEGFR-3",
            "VEGFR3"
        ]
    },
    "variant": "over exp",
    "createDate": "04/23/2015",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3857,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, advanced medullary thyroid cancer patients with high soluble Flt4 expression were more likely to display tumor reduction when treated with Lenvima (lenvatinib) (PMID: 26311725).",
            "molecularProfile": {
                "id": 5012,
                "profileName": "FLT4 over exp"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4237,
                    "pubMedId": 26311725,
                    "title": "A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311725"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5012,
            "profileName": "FLT4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}